Eurofins Discovery Publishes Breakthrough SH2scan Study: Mapping SH2 Domain Selectivity at Scale
NEWS PROVIDED BY:
Eurofins Discovery
SAN DIEGO, CA – February 25, 2026 — Eurofins Discovery announces their latest publication, SH2scan®: Mapping SH2 Domain-Ligand Binding Selectivity for Inhibitors and Degraders, on the cover of the Journal of Medicinal Chemistry showcasing SH2scan, a high-throughput assay platform that profiles SH2 domain-ligand interactions across >80% of canonical SH2 domains. This study delivers unprecedented insights into selectivity and off-target binding for SH2-targeting compounds.
Key Findings:
- Comprehensive Coverage: SH2scan evaluated 95 constructs representing >80% of SH2 domains.
- Nine Ligands Profiled: Including inhibitors and a heterobifunctional degrader, revealing diverse selectivity signatures.
- Binding Promiscuity vs. Selectivity: Some ligands (e.g., caffeic acid-pYEEIE) bound up to 70% of constructs, while others showed narrow profiles.
- Off-Target Detection: Unexpected interactions identified early, reducing pharmacological risk.
- SAR Impact: Demonstrated how small chemical changes (e.g., STAT6-IN-1 vs. STAT6-IN-3) dramatically alter selectivity.
Understanding selectivity is critical for reducing off-target effects and improving therapeutic outcomes and SH2scan provides the chemical biology community with a powerful tool to accelerate discovery.
Read the full publication: https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5c02613
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
